Cytokines as potential combination agents with PD‐1/PD‐L1 blockade for cancer treatment-Reference-Cited by-同舟云学术

Cytokines as potential combination agents with PD‐1/PD‐L1 blockade for cancer treatment

Published:2020-01-22 Issue:7-8 Volume:235 Page:5449-5460
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J Cell Physiol

Author:

Rahimi Kalateh Shah Mohammad Ghasem¹,Ghahremanloo Atefeh²³,Soltani Arash²³,Fathi Esmat⁴,Hashemy Seyed Isaac²⁵^ORCID

Affiliation:

1. Department of Biology, Mashhad BranchIslamic Azad University Mashhad Iran

2. Department of Clinical Biochemistry, Faculty of MedicineMashhad University of Medical Sciences Mashhad Iran

3. Student Research Committee, Faculty of MedicineMashhad University of Medical Sciences Mashhad Iran

4. Department of Biological SciencesUniversity of Memphis Memphis Tennessee

5. Surgical Oncology Research CenterMashhad University of Medical Sciences Mashhad Iran

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcp.29491

Reference137 articles.

1. Inhibition of constitutive STAT3 activity sensitizes resistant non‐Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug‐mediated apoptosis;Alas S.;Clinical Cancer Research,2003

2. Algazi A. Tsai K. K. Takamura K. T. Chen L. Twitty C. Dwyer M. …Daud A.Abstract CT134: Intratumoral electroporation of plasmid IL‐12 can prime response to anti‐PD1/PD‐L1 blockade in patients with Stage III/IV‐M1a melanoma.Proceedings of the AACR 107th Annual Meeting 2016; April 16‐20 2016;New Orleans LA. Retrieved from 10.1158/1538‐7445.AM2016‐CT134

3. The Use of Cytokines and Chemokines in the Cancer Immunotherapy

4. Interleukin-10 Therapy—Review of a New Approach

5. High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Roles of the tumor microenvironment in the resistance to programmed cell death protein 1 inhibitors in patients with gastric cancer;World Journal of Gastrointestinal Oncology;2024-09-15

2. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy;Journal of Translational Medicine;2024-08-09

3. Qingfei mixture mitigates immunosuppression of tumor microenvironment in non-small cell lung cancer by blocking stat1/Ido1-mediated tryptophan-kynurenine pathway;Heliyon;2024-06

4. Intratumoral IL-12 delivery via mesenchymal stem cells combined with PD-1 blockade leads to long-term antitumor immunity in a mouse glioblastoma model;Biomedicine & Pharmacotherapy;2024-04

5. Soy isoflavone genistein attenuates the efficacy of immune checkpoint therapy in C57BL/6 mice inoculated with B16F1 melanoma and a high PD-‍L1 expression level reflects tumor resistance;Journal of Clinical Biochemistry and Nutrition;2024